BioLineRx Ltd.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BioLineRx Ltd. operates as a commercial-stage biopharmaceutical firm, strategically advancing therapeutic solutions for oncology and select rare diseases. The company's lead product, APHEXDA (motixafortide), received U.S. Food and Drug Administration approval in September 2023. APHEXDA is indicated for use in conjunction with filgrastim, facilitating the mobilization of hematopoietic stem cells for collection and subsequent autologous transplantation in patients battling multiple myeloma. Its commercialization is managed through partnerships, with Ayrmid Ltd. handling global distribution outside of Asia, and Gloria Biosciences overseeing development and commercial activities across Asia. Beyond its approved therapy, BioLineRx continues to develop motixafortide for other critical needs. It is currently under investigation in a randomized Phase 2b clinical trial, sponsored by Columbia University, exploring its potential for treating first-line metastatic pancreatic cancer in combination with a PD-1 inhibitor and chemotherapy. Furthermore, a Phase 1 clinical trial is underway to assess motixafortide for mobilizing CD34+ hematopoietic stem cells, aimed at supporting gene therapies for individuals with sickle cell disease. The pipeline also includes AGI-134, an intratumoral cancer vaccine candidate targeting solid tumors. Its Phase 1/2a clinical investigation has concluded, demonstrating favorable safety and tolerability, alongside evidence of immune system activation. Additionally, BioLineRx has established a joint venture to progress GLIX1, an innovative oral small molecule designed to modulate the DNA damage response in various cancers, including glioblastoma. A Phase 1/2a study for GLIX1 is slated to commence in early 2026. BioLineRx Ltd., established in 2003, maintains its headquarters in Modi'in, Israel.
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
BioLineRx (BLRX) Projected to Post Quarterly Earnings on Monday
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings
BioLineRx to Report 2025 Annual Results on March 23, 2026
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
BioLineRx Ltd. - Special Call
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript